+357 96 030922
info@marketpublishers.com

JAK Inhibitors – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Market -

https://marketpublishers.com/r/J97D94E83471EN.html
Date: July 2025
Pages: 0
Price: US$ 3,400.00 (Single User License)
ID: J97D94E83471EN

Contents

+357 96 030922
info@marketpublishers.com

• Currently, there is only one Janus kinase inhibitors drug that is commercially available in the market by approving Ruxolitinib.
• Although this drug is approved for the treatment of rare hematological malignancies occurrence rate of these cancers has been increasing in the past years. Further, the lack of effective treatment for these cancers and higher survival rates of the patients after treatment with Ruxolitinib has aided the commercial success of Ruxolitinib. And 27 drugs are found to be in various clinical development phases.
• Most of the drugs are in Preclinical phase followed by the Phase-II clinical trials. There are six drugs in Phase III clinical trial including baricitinib for the treatment of rheumatoid arthritis.
• Itacitinib has reached into Phase II clinical trial phase for the treatment of primary myelofibrosis, non-small cell lung cancer, post-polycythemia vera myelofibrosis, and refractory Hodgkin lymphoma. CTP-543, a Phase I drug candidate is developing for alopecia area.
• It is an inhibitor of JAK1 and JAK2 that is involved in autoimmune disease. A pre-clinical drug candidate ATI-50001 is developing for the treatment of alopecia. The Promising Candidates in the Clinical Pipeline includes Momelotinib, Lestaurtinib, Pacritinib.
• More than 5 JAK inhibitors are expected to enter into the market in the next decade. The development of JAK inhibitors has been so impressive and fastest in the past five years and thus expecting a tremendous economic success of this class of drugs in the nearby future.
• Furthermore, substantial commercial success of the Ruxolitinib JAK inhibitor for myeloproliferative disorders further accelerated the development of more JAK inhibitors in the market.
• Advances in research and technology will add to the development of JAK inhibitors. The development of more JAK inhibitors will not only provides benefits to the therapeutic cancer market but will also add a better life from cancers to the patients.
MARKET OUTLOOK
• Janus kinase (JAK) inhibitors block the Janus kinase activator enzymes thereby interrupting signaling pathway. JAK inhibitors target the process leading to the production of the damaged DNA that is playing the major role in producing cancerous cells.
• Many signal transduction pathways have to be done by JAK activity to induce normal signaling. The abnormal variation in JAKs activity will lead to a diseased condition. For example, overactivation of JAK will lead to tumorigenesis whereas loss of JAK will lead to severe combined immunodeficiency. Janus Kinases family includes JAK 1, JAK 2, JAK 3 and also a group of cytoplasmic non-receptor Tyrosine kinases (NRTKs).
• The JAKs present on the surface of cells got associated with cytokine receptor. JAK

+357 96 030922
info@marketpublishers.com

tyrosine kinase family is firstly associated with signal transduction coming from extracellular ligands that will often interact with transmembrane receptors.
• Different ones of JAK tyrosine kinase are the critical elements in mediating signaling processes like an expression of genes that are involved in the process of proliferation, apoptosis, migration, and differentiation.
• They play an essential role in immune defense action as many signaling events involved in innate and adaptive immunity is mediated by JAKs. They are also associated with cell growth, survival, development, and differentiation of immune cells. Thus mutation in JAKs is leading to the immunodeficiency disorders.

THE SCOPE OF THE REPORT

• Provides comprehensive understanding of active JAK inhibitors pipeline drug candidates
• Includes complete pipeline product coverage with segregation by various stages of the pipeline from discovery to late-stage.
• Offers pipeline assessment by monotherapy, combination therapy products, and route of administration
• Provides a comparative analysis of key marketed products and pipeline drug candidates
• Includes detailed pipeline drug profiles covering – product description, chemical information, molecule type, mechanism of action, route of administration, product safety and efficacy, developers and collaborators
• Provides essential info on players involved in clinical R&D of JAK inhibitors drug candidates.
• Provides in-depth coverage of crucial news related to JAK inhibitors drug molecules, including significant mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates.

WHY SHOULD I PURCHASE THIS REPORT?

• To obtain an understanding of the current JAK inhibitors pipeline landscape.
• To determine drug development dynamics and leverage it for innovation of novel or repositioned drugs.
• To valuably optimize R&D activities in-line with robust therapeutic drug markets.
• To devise strategic initiatives by identifying prospective partners with progressing projects.

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: JAK Inhibitors – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Market -

Product link: https://marketpublishers.com/r/J97D94E83471EN.html

Price: US$ 3,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/J97D94E83471EN.html